
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Paris - Results from a series of studies conducted at the Skin Research Laboratory of the Technion-Israel Institute of Technology are providing important insights about the pathogenesis of alopecia areata and a basis for exploring new immunomodulating therapies for the disorder.